Prostate Cancer and Prostatic Diseases

Article	Citations
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	121
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	90
Concerns regarding prostate cancer screening guidelines in minority populations	66
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	65
Correction to: Advances in PSMA-targeted therapy for prostate cancer	62
More evidence that physical activity is beneficial for prostate cancer	58
Best of 2022 in prostate cancer and prostatic diseases	54
The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis	43
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	41
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer	41
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	41
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	40
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	39
Germline alterations among Hispanic men with prostate cancer	38
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	37
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	36
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	33
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	32
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	32
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	32
Incidence of prostate cancer in transgender women in the US: a large database analysis	31
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	30
18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review	30
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	28
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	27

Focal therapy for prostate cancer—ready to be a standard of care?	26
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	26
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	26
TRexit is going one step further	26
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	26
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	25
LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations	25
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	24
The microbiome and prostate cancer	24
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	24
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	23
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	23
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	23
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	22
Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study	22
Exercise medicine in men with prostate cancer: breaking barriers to increase participation	22
Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days’ follow-up	22
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy	22
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	22
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	22
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature	22
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	21
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT	20
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants	20
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients	20
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients	20
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	20
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)	20
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	20
Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database	20
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	20
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction	19
The effects of glycemic index on prostate cancer progression in a xenograft mouse model	19
Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?	19
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials	19
Antimicrobial prophylaxis: To do or not to do? This is the question	19
The evolving clinical use of prostate cancer biomarkers	19
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study	19
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate	18
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK	18
The times have changed. Let the urologists change!	18
Prognostic value of MR visibility/invisibility in men on Active Surveillance	18
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	18
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells	18
Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system	17
Association of prostate cancer with human papillomavirus infections: a case-control study	17
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	17
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	17
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics	17
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry	17

Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!	17
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey	17
Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia	17
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	16
The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis	16
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	16
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis	16
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy	16
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan	16
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer	16
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification	16
Correction: Estimating patient health in prostate cancer treatment counseling	15
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study	15
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	15
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial	15
Sleep disturbances are underappreciated in prostate cancer survivorship	15
Risk calculators for the detection of prostate cancer: a systematic review	15
Prevalence and determinants of shared decision-making for PSA testing in the United States	14
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy	14
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	14
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications	14
Less is more: the “Safety Net Approach” balances precision and safety	14
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials	14
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer	14
Characteristics of incidental prostate cancer in the United States	14
Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review	14
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores	14
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape	14
Cardiovascular risk in ADT recipients: does the type of ADT matter?	14
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer	14
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review	14
Drivers of racial disparities in prostate cancer trial enrollment	13
The obesity paradox in metastatic castration-resistant prostate cancer	13
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	13
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN	13
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey	13
Can there be consensus on whether vasectomy is a prostate cancer risk factor?	13
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	13
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis	13
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?	13
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	13
Hyperglycemia and microRNAs in prostate cancer	12
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	12
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	12
The impact of race on survival in metastatic prostate cancer: a systematic literature review	12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	12
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	12
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	11
The changing face of castrate resistant prostate cancer	11
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer	11
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	11
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	11
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	11
Best of 2023 in Prostate Cancer and Prostatic Diseases	11
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	11
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	11
Quality of information and appropriateness of ChatGPT outputs for urology patients	11
Biopsy strategies in the era of mpMRI: a comprehensive review	11
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	10
Overcoming barriers to prostate cancer genetic testing: who, when, and how	10
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control	10
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	10
Quality of information and appropriateness of Open AI outputs for prostate cancer	10
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	10
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients	10
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	10
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer	10
Prostate cancer and prostatic diseases is “Your” journal	10
Surveillance after Focal Therapy – a Comprehensive Review	10
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes	10
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration	10
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry	10
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	10
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis	10
New robotic platforms for prostate surgery: the future is now	9
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	9
Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study	9
Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study	9
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care	9

Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24	9
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer	9
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in i	9
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT	9
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer	9
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	9
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016	9
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	9
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer	9
Quality of information and appropriateness of ChatGPT outputs for urology patients	9
Androgen deprivation therapy and acute kidney injury in prostate cancer: room for debate?	9